Vol. 6 No. 7 (2026): July
Reimbursement Reviews

Pegcetacoplan (Empaveli)

decorative image of the issue cover

Published July 31, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Pegcetacoplan (Empaveli), 1,080 mg/20 mL (54 mg/mL) solution for subcutaneous infusion.
  • Indication: Proposed: For the treatment of adults and adolescents aged 12 years and older with C3G or primary IC-MPGN.